ASCO: Bristol Myers delves into Opdualag's LAG-3 melanoma win in key populations ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups ASCO: Merck's Keytruda combo data could spark hope for lymphoma patients who lack options ASCO: Genentech touts bispecific data for DLBCL, calling it 'groundbreaking' for heavily pretreated patients ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population ASCO: J&J's multiple myeloma toolkit expands with bispecifics data ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data ASCO: Is another pan-tumor drug on the horizon? Johnson & Johnson thinks Balversa could be it ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug ASCO: I-Mab, Junshi's cancer combo performs best as a first-line NSCLC treatment, with signals for CD73 as a biomarker 'The Top Line' podcast: How biopharma is tackling the monkeypox outbreak, insight on nominations for our Fierce 15 list, plus this week's headlines Featured Story | By Angus Liu Bristol Myers Squibb made history in March by introducing the first LAG-3 drug as part of an Opdivo combo called Opdualag. As the first in a new cancer immunotherapy class, Opdualag now has additional data to back its use in various melanoma patients, which is being presented at ASCO 2022. read more |
| |
|---|
|
Top Stories By Angus Liu As biopharma industry watchers wait to see whether Keytruda will hit its goal as a postsurgery treatment in early lung cancer patients with high tumor expressions of the PD-L1 biomarker, Merck & Co. is rolling out new data to show the drug’s benefits across other patient groups. read more By Annalee Armstrong For Merck, the show has been all about Keytruda, as well as Lynparza and Lenvima, in oncology for the past few years. But the New Jersey pharma is hoping to soon have some supporting players to add to the playbill. read more By Annalee Armstrong Genentech will show pivotal data from the phase 2 diffuse large B-cell lymphoma trial of glofitamab at the 2022 American Society of Clinical Oncology conference in June. The data comes from 155 patients who had received at least three prior lines of therapy, according to Ginna Laport, Genentech’s vice president and Global Head of the Lymphoma/CLL Development franchise. read more By Angus Liu Johnson & Johnson and Legend Biotech showed that their closely watched CAR-T therapy, Carvykti, sustained an effect in heavily pretreated multiple myeloma patients and shrank tumors when given earlier in a population with otherwise unyielding disease. read more By Annalee Armstrong Multiple myeloma is still an uncurable cancer, but Johnson & Johnson’s Janssen unit is building a toolkit to fight back. The latest additions are the bispecific antibodies teclistamab and talquetamab, both being tested in heavily pretreated patients. Janssen will showcase data on both therapies at the American Society of Clinical Oncology meeting in June. read more By Angus Liu Novartis boasts an accelerated approval for its blockbuster-to-be Scemblix in previously treated chronic myeloid leukemia. Now with new clinical data, the company hopes to turn it into a full nod. read more By Angus Liu The FDA has only approved a handful of therapies to treat tumors based on a biomarker and regardless of their location. With new clinical data, Johnson & Johnson hopes Balversa could be the next drug up for a pan-tumor nod. read more By Kevin Dunleavy During the American Society of Clinical Oncology (ASCO) conference, Seagen and Takeda presented trial data that show Adcetris could become at growing force in the treatment of various forms of lymphoma. read more By Max Bayer Early phase 2 data of I-Mab’s antibody coupled with Junshi Biosciences’ immuno-oncology drug shows it performed best among untreated non-small cell lung cancer patients, and a biomarker may help identify the ideal patient pool. Results from the China-based trial, which tests I-Mab’s CD73 antibody uliledlimab alongside Junshi's PD-1 inhibitor toripalimab, were released Thursday at ASCO. read more By Teresa Carey This week on "The Top Line," we discuss the new monkeypox outbreak, what the treatment options are and why health officials don’t seem concerned. We also talk about Dexcom's potential megamerger with Insulet, the upcoming ASCO meeting and the week's other big headlines. Plus, we have a special announcement about the prestigious Fierce 15 competition. read more Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 